BioNTech Cost Of Revenue from 2010 to 2025

BNTX Stock  USD 112.92  4.12  3.79%   
BioNTech Cost Of Revenue yearly trend continues to be fairly stable with very little volatility. Cost Of Revenue will likely drop to about 655.3 M in 2025. During the period from 2010 to 2025, BioNTech Cost Of Revenue regression line of annual values had r-squared of  0.22 and arithmetic mean of  762,561,406. View All Fundamentals
 
Cost Of Revenue  
First Reported
2018-06-30
Previous Quarter
59.8 M
Current Value
178.9 M
Quarterly Volatility
487.1 M
 
Covid
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Tax Provision of 279.5 M, Net Interest Income of 422.3 M or Interest Income of 431.8 M, as well as many indicators such as Price To Sales Ratio of 6.54, Dividend Yield of 0.011 or PTB Ratio of 1.07. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
  
Check out the analysis of BioNTech Correlation against competitors.

Latest BioNTech's Cost Of Revenue Growth Pattern

Below is the plot of the Cost Of Revenue of BioNTech SE over the last few years. Cost of Revenue is found on BioNTech SE income statement and represents the costs associated with goods and services BioNTech provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is BioNTech's Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.
Cost Of Revenue10 Years Trend
Slightly volatile
   Cost Of Revenue   
       Timeline  

BioNTech Cost Of Revenue Regression Statistics

Arithmetic Mean762,561,406
Geometric Mean270,750,342
Coefficient Of Variation179.35
Mean Deviation858,447,148
Median156,730,000
Standard Deviation1,367,650,685
Sample Variance1870468.4T
Range4.4B
R-Value0.47
Mean Square Error1563884.6T
R-Squared0.22
Significance0.07
Slope134,630,673
Total Sum of Squares28057025.9T

BioNTech Cost Of Revenue History

2025655.3 M
2024689.8 M
2023599.8 M
20224.5 B
20213.9 B
2020704.4 M
2019243.8 M

About BioNTech Financial Statements

BioNTech investors use historical fundamental indicators, such as BioNTech's Cost Of Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioNTech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue689.8 M655.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.